By 
Podcast Services: Apple Podcasts • Google Podcasts • Spotify Podcasts
Dr. Ragan discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM Syndrome and two Phase 1b trials for Waldenstrom macroglobulinemia (WM), a type of rare lymphoma, and severe congenital neutropenia (SCN).
X4 Website: https://www.x4pharma.com
X4 Twitter: https://twitter.com/x4pharma
X4 LinkedIn: https://www.linkedin.com/company/x4-pharmaceuticals